For instance, MCLA-158 (petosemtamab), a BsAb targeting both EGFR and LGR5, exhibited strong growth inhibition of patient-derived CRC organoids and orthotopic xenograft tumor models, including KRAS mutant CRCs resistant to cetuximab [184]. This evidence concerns the gene LGR5 and neoplasm.